2. Activity Goals

3. Discussion Topics

4. Current Treatment Paradigm for Locally Advanced/Metastatic Bladder Cancer

5. Challenges With Cisplatin-Based Therapy

6. Discovery of Bacillus Calmette-Guérin (BCG)

7. T-Cell Biology

8. The Use of Immunotherapy in Bladder Cancer -- Checkpoint Inhibition Strategies

9. KEYNOTE-012: Pembrolizumab in Advanced Bladder Cancer

10. KEYNOTE-012: Results

11. KEYNOTE-012: Response Duration and Safety

12. IMvigor 210: Atezolizumab in mUC

13. IMvigor 210: Patient Population

14. IMvigor 210: Response Rates

15. IMvigor 210: Durable Responses

16. IMvigor 210: Overall Survival

17. IMvigor 210: Adverse Events

18. JAVELIN Trial: Avelumab in mUC

19. JAVELIN Trial: Results

20. Phase 2: Gemcitabine + Cisplatin + Ipilimumab in mUC

21. Gemcitabine + Cisplatin + Ipilimumab in mUC: Trial Design

22. Gemcitabine + Cisplatin + Ipilimumab in mUC: Results

23. Gemcitabine + Cisplatin + Ipilimumab in mUC: Safety

24. Biomarkers of Response: Who Benefits From Immunotherapy?

25. Relationship Between Immune-Related Gene Expression Signatures and Outcomes

26. Populations of Interest

27. Selected Enrolling Clinical Trials: Pembrolizumab

28. Selected Enrolling Clinical Trials: Nivolumab and Ipilimumab

29. Selected Enrolling Clinical Trials: Atezolizumab

30. Selected Enrolling Clinical Trials: Avelumab

31. Abbreviations

32. Abbreviations (cont)